Post-earnings recap
Reported
Mon, Nov 22, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's earnings report indicates ongoing challenges, particularly reflected in the negative EPS. The stock fell by 11.25% following the announcement, likely due to investor disappointment over the lack of revenue details and guidance. This suggests uncertainty about the company's near-term performance and market conditions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | -5.40% |
| Revenue | N/A | N/A | N/A |
Management's tone was cautious, reflecting the difficulties encountered. They did not offer specific guidance for future performance.
Management did not provide specific details on revenue expectations.
The company acknowledged challenges faced during the quarter.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—